A case of pneumocystis pneumonia after Cetuximab-based bioradiotherapy

Asano Shinohara; Ryunosuke Kogo; Hideoki Uryu; Ryuji Yasumatsu; Torahiko Nakashima; Shizuo Komune

doi:10.3950/jibiinkoka.119.204

A case of pneumocystis pneumonia after Cetuximab-based bioradiotherapy

Asano Shinohara, Ryunosuke Kogo, Hideoki Uryu, Ryuji Yasumatsu, Torahiko Nakashima, Shizuo Komune

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Reports of drug-induced interstitial pneumonia caused by Cetuximab have been increasing. Pneumocystis pneumonia is important as a differential diagnosis of drug-induced interstitial pneumonia. We report herein on a 64-year-old man with pneumocystis pneumonia after cetuximab-based bioradiotherapy for laryngeal cancer. After radiotherapy, the patient developed multi-drug resistant pneumonia. Chest CT imaging revealed diffuse ground-glass opacities in the lung field. He was diagnosed as having pneumocystis pneumonia based on the bronchoalveolar lavage (BAL) findings, and then his symptoms improved after treatment with Trimethoprim/Sulfamethoxazole. It is important to assess the risk factor for pneumocystis pneumonia for early its detection and treatment.

Original language	English
Pages (from-to)	204-209
Number of pages	6
Journal	Journal of Otolaryngology of Japan
Volume	119
Issue number	3
DOIs	https://doi.org/10.3950/jibiinkoka.119.204
Publication status	Published - 2016

All Science Journal Classification (ASJC) codes

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3950/jibiinkoka.119.204

Cite this

@article{a195c6536faf4d1e9e7e7487d1303ba5,

title = "A case of pneumocystis pneumonia after Cetuximab-based bioradiotherapy",

abstract = "Reports of drug-induced interstitial pneumonia caused by Cetuximab have been increasing. Pneumocystis pneumonia is important as a differential diagnosis of drug-induced interstitial pneumonia. We report herein on a 64-year-old man with pneumocystis pneumonia after cetuximab-based bioradiotherapy for laryngeal cancer. After radiotherapy, the patient developed multi-drug resistant pneumonia. Chest CT imaging revealed diffuse ground-glass opacities in the lung field. He was diagnosed as having pneumocystis pneumonia based on the bronchoalveolar lavage (BAL) findings, and then his symptoms improved after treatment with Trimethoprim/Sulfamethoxazole. It is important to assess the risk factor for pneumocystis pneumonia for early its detection and treatment.",

author = "Asano Shinohara and Ryunosuke Kogo and Hideoki Uryu and Ryuji Yasumatsu and Torahiko Nakashima and Shizuo Komune",

year = "2016",

doi = "10.3950/jibiinkoka.119.204",

language = "English",

volume = "119",

pages = "204--209",

journal = "Journal of Otolaryngology of Japan",

issn = "0030-6622",

publisher = "Oto-Rhino-Laryngological Society of Japan Inc.",

number = "3",

}

TY - JOUR

T1 - A case of pneumocystis pneumonia after Cetuximab-based bioradiotherapy

AU - Shinohara, Asano

AU - Kogo, Ryunosuke

AU - Uryu, Hideoki

AU - Yasumatsu, Ryuji

AU - Nakashima, Torahiko

AU - Komune, Shizuo

PY - 2016

Y1 - 2016

N2 - Reports of drug-induced interstitial pneumonia caused by Cetuximab have been increasing. Pneumocystis pneumonia is important as a differential diagnosis of drug-induced interstitial pneumonia. We report herein on a 64-year-old man with pneumocystis pneumonia after cetuximab-based bioradiotherapy for laryngeal cancer. After radiotherapy, the patient developed multi-drug resistant pneumonia. Chest CT imaging revealed diffuse ground-glass opacities in the lung field. He was diagnosed as having pneumocystis pneumonia based on the bronchoalveolar lavage (BAL) findings, and then his symptoms improved after treatment with Trimethoprim/Sulfamethoxazole. It is important to assess the risk factor for pneumocystis pneumonia for early its detection and treatment.

AB - Reports of drug-induced interstitial pneumonia caused by Cetuximab have been increasing. Pneumocystis pneumonia is important as a differential diagnosis of drug-induced interstitial pneumonia. We report herein on a 64-year-old man with pneumocystis pneumonia after cetuximab-based bioradiotherapy for laryngeal cancer. After radiotherapy, the patient developed multi-drug resistant pneumonia. Chest CT imaging revealed diffuse ground-glass opacities in the lung field. He was diagnosed as having pneumocystis pneumonia based on the bronchoalveolar lavage (BAL) findings, and then his symptoms improved after treatment with Trimethoprim/Sulfamethoxazole. It is important to assess the risk factor for pneumocystis pneumonia for early its detection and treatment.

UR - http://www.scopus.com/inward/record.url?scp=84964403737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964403737&partnerID=8YFLogxK

U2 - 10.3950/jibiinkoka.119.204

DO - 10.3950/jibiinkoka.119.204

M3 - Article

C2 - 27244906

AN - SCOPUS:84964403737

VL - 119

SP - 204

EP - 209

JO - Journal of Otolaryngology of Japan

JF - Journal of Otolaryngology of Japan

SN - 0030-6622

IS - 3

ER -

A case of pneumocystis pneumonia after Cetuximab-based bioradiotherapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this